Role of the Gut Sweet Taste Receptor in the Secretion of Glucagon-like Peptide-1 and Peptide YY

This study has been completed.
Sponsor:
Information provided by:
University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier:
NCT01304823
First received: February 22, 2011
Last updated: February 24, 2011
Last verified: February 2011
  Purpose

The purpose of this study is to determine the functional significance of sweet taste receptors in the secretion of GI satiation peptides by using a specific sweet taste receptor antagonist to block sweet taste perception in the gastrointestinal tract.


Condition Intervention Phase
Taste Disorder, Primary, Sweet
Dietary Supplement: lactisole
Other: mixed liquid meal
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: The Role of Sweet Taste Receptor Blockade on Intraduodenal Glucose- and Liquid Meal-stimulated Secretion of Satiation Peptides in Healthy Humans

Resource links provided by NLM:


Further study details as provided by University Hospital, Basel, Switzerland:

Primary Outcome Measures:
  • Gastrointestinal peptide secretion [ Time Frame: 4 hours blood sampling ] [ Designated as safety issue: No ]
    Assessment of venous GLP-1 and PYY release to meal stimulation with and without sweet receptor blockade


Secondary Outcome Measures:
  • Appetite perceptions during 4 hours using VAS [ Time Frame: 4 hours ] [ Designated as safety issue: No ]
    Assessment of the following appetite perception markers: feelings of hunger, feelings of fullness, feelings of satiety using validated visual analogue scales


Enrollment: 10
Study Start Date: June 2010
Study Completion Date: January 2011
Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: glucose
intraduodenal perfusion of glucose (29.3 g glucose per 100 mL; rate: 2.5 mL/min for 180 min; caloric load: 3.0 kcal/min)
Dietary Supplement: lactisole
flavoring agent/sweet taste antagonist
Other Name: Dietary supplement
Active Comparator: glucose + lactisole
intraduodenal perfusion of glucose (29.3 g glucose per 100 mL; rate: 2.5 mL/min for 180 min; caloric load: 3.0 kcal/min) + 450 ppm lactisole
Dietary Supplement: lactisole
flavoring agent/sweet taste antagonist
Other Name: Dietary supplement
Active Comparator: mixed liquid meal
intraduodenal perfusion of a mixed liquid meal (20.20 g carbohydrate, 4.92 g fat and 6.25 g protein per 100 mL; rate: 2.5 mL/min for 180 min; caloric load: 3.0 kcal/min)
Other: mixed liquid meal
Ensure Plus
Other Name: Dietary supplement
Active Comparator: mixed liquid meal + lactisole
intraduodenal perfusion of a mixed liquid meal (20.20 g carbohydrate, 4.92 g fat and 6.25 g protein per 100 mL; rate: 2.5 mL/min for 180 min; caloric load: 3.0 kcal/min) + 450 ppm lactisole
Other: mixed liquid meal
Ensure Plus
Other Name: Dietary supplement
Placebo Comparator: saline + lactisole
saline (0.9 %; rate: 2.5 mL/min for 180 min) + 450 ppm lactisole
Dietary Supplement: lactisole
flavoring agent/sweet taste antagonist
Other Name: Dietary supplement

Detailed Description:

There is strong evidence that taste signaling mechanisms identified in the oral epithelium also operate in the gut. It is suggested that open-type enteroendocrine cells directly sense nutrient via alpha-gustducin coupled taste receptors to modulate the secretion of glucagon like peptide-1 (GLP-1) and peptide YY (PYY). Several nutrient responsive G-protein coupled receptors have been identified in the human gut, including the sweet taste responsive T1R2/T1R3 heterodimer, the amino acid/umami responsive T1R1/T1R3 as well as GPR120 for unsaturated long-chain free fatty acids.The functional significance of sweet taste receptors in the secretion of GLP-1 and PYY will be determined by intraduodenal perfusion of glucose (I) or a mixed liquid meal (II) with or without lactisole (450 ppm) in a double blind, 5-way crossover trial including 10 healthy subjects.

  Eligibility

Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy subjects
  • BMI of 19.0-24.5
  • Age 18-40
  • stable body weight for at least 3 month

Exclusion Criteria:

  • smoking
  • substance abuse
  • regular intake of medication
  • medical or psychiatric illness
  • gastrointestinal disorders or food allergies
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01304823

Locations
Switzerland
University Hospital Basel, Phase 1 Research Unit
Basel, Switzerland, 4031
Sponsors and Collaborators
University Hospital, Basel, Switzerland
Investigators
Principal Investigator: Christoph Beglinger, MD Phase 1 Research Unit, University Hospital Basel
  More Information

No publications provided by University Hospital, Basel, Switzerland

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Beglinger Christoph, Prof. Dr. med., Department of Gastroenterology, University Hospital Basel, Basel, Switzerland
ClinicalTrials.gov Identifier: NCT01304823     History of Changes
Other Study ID Numbers: EKBB 69/04.03
Study First Received: February 22, 2011
Last Updated: February 24, 2011
Health Authority: Switzerland: Ethikkommission

Keywords provided by University Hospital, Basel, Switzerland:
T1R2/T1R3
gastric emptying
gut
lactisole
nutrient sensing

Additional relevant MeSH terms:
Taste Disorders
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Glucagon-Like Peptide 1
Glucagon
Incretins
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions
Gastrointestinal Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on August 27, 2014